These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36308299)

  • 1. Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial.
    Tanaka A; Sata M; Okada Y; Teragawa H; Eguchi K; Shimabukuro M; Taguchi I; Matsunaga K; Kanzaki Y; Yoshida H; Ishizu T; Ueda S; Kitakaze M; Murohara T; Node K;
    Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):165-172. PubMed ID: 36308299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
    Tanaka A; Murohara T; Taguchi I; Eguchi K; Suzuki M; Kitakaze M; Sato Y; Ishizu T; Higashi Y; Yamada H; Nanasato M; Shimabukuro M; Teragawa H; Ueda S; Kodera S; Matsuhisa M; Kadokami T; Kario K; Nishio Y; Inoue T; Maemura K; Oyama J; Ohishi M; Sata M; Tomiyama H; Node K;
    Cardiovasc Diabetol; 2016 Sep; 15(1):133. PubMed ID: 27619983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.
    Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
    Cardiovasc Diabetol; 2020 Jul; 19(1):110. PubMed ID: 32646498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
    Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
    PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary quality and carotid intima media thickness in type 1 and type 2 diabetes: Follow-up of a randomised controlled trial.
    Petersen KS; Keogh JB; Lister NB; Clifton PM
    Nutr Metab Cardiovasc Dis; 2018 Aug; 28(8):830-838. PubMed ID: 29853429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term observation of estimated fluid volume reduction after the initiation of ipragliflozin in patients with type 2 diabetes mellitus: a sub-analysis from a randomized controlled trial (PROTECT).
    Tanaka A; Imai T; Toyoda S; Sugimoto K; Yoshida R; Furuta M; Node K;
    Diabetol Metab Syndr; 2023 Jul; 15(1):152. PubMed ID: 37415229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
    Mita T; Katakami N; Shiraiwa T; Yoshii H; Onuma T; Kuribayashi N; Osonoi T; Kaneto H; Kosugi K; Umayahara Y; Yamamoto T; Matsumoto K; Yokoyama H; Tsugawa M; Gosho M; Shimomura I; Watada H;
    Diabetes Care; 2016 Mar; 39(3):455-64. PubMed ID: 26822324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial.
    Lundby-Christensen L; Vaag A; Tarnow L; Almdal TP; Lund SS; Wetterslev J; Gluud C; Boesgaard TW; Wiinberg N; Perrild H; Krarup T; Snorgaard O; Gade-Rasmussen B; Thorsteinsson B; Røder M; Mathiesen ER; Jensen T; Vestergaard H; Hedetoft C; Breum L; Duun E; Sneppen SB; Pedersen O; Hemmingsen B; Carstensen B; Madsbad S
    BMJ Open; 2016 Feb; 6(2):e008377. PubMed ID: 26916685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease.
    Koyasu M; Ishii H; Watarai M; Takemoto K; Inden Y; Takeshita K; Amano T; Yoshikawa D; Matsubara T; Murohara T
    Clin Ther; 2010 Aug; 32(9):1610-7. PubMed ID: 20974318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall-a sub-analysis of the UTOPIA trial.
    Katakami N; Mita T; Maeda N; Sato Y; Watada H; Shimomura I;
    Cardiovasc Diabetol; 2022 Feb; 21(1):19. PubMed ID: 35123483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
    Tanaka M; Yamakage H; Inoue T; Odori S; Kusakabe T; Shimatsu A; Satoh-Asahara N
    Intern Med; 2020; 59(5):601-609. PubMed ID: 32115517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CETP activity is not associated with carotid intima-media thickness in patients with poorly controlled type 2 diabetes.
    Bouillet B; Gautier T; Terriat B; Lagrost L; Verges B; Petit JM
    Acta Diabetol; 2019 Jul; 56(7):749-754. PubMed ID: 30980187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of acarbose to delay progression of carotid intima-media thickness in early diabetes.
    Patel YR; Kirkman MS; Considine RV; Hannon TS; Mather KJ
    Diabetes Metab Res Rev; 2013 Oct; 29(7):582-91. PubMed ID: 23908125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of ipragliflozin on blood pressure in patients with type 2 diabetes: insights from the randomized PROTECT trial.
    Saito Y; Tanaka A; Imai T; Nakamura I; Kanda J; Matsuhisa M; Uehara H; Kario K; Kobayashi Y; Node K;
    Hypertens Res; 2024 Jan; 47(1):168-176. PubMed ID: 37964067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
    Kitazawa M; Katagiri T; Suzuki H; Matsunaga S; H Yamada M; Ikarashi T; Yamamoto M; Furukawa K; Iwanaga M; Hatta M; Fujihara K; Yamada T; Tanaka S; Sone H
    Diabetes Obes Metab; 2021 Mar; 23(3):811-821. PubMed ID: 33416200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study.
    Kishimoto S; Higashi Y; Imai T; Eguchi K; Fukumoto K; Tomiyama H; Maemura K; Tanaka A; Node K;
    Cardiovasc Diabetol; 2023 May; 22(1):119. PubMed ID: 37210524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
    Han KA; Chon S; Chung CH; Lim S; Lee KW; Baik S; Jung CH; Kim DS; Park KS; Yoon KH; Lee IK; Cha BS; Sakatani T; Park S; Lee MK
    Diabetes Obes Metab; 2018 Oct; 20(10):2408-2415. PubMed ID: 29862619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial.
    Oyama J; Murohara T; Kitakaze M; Ishizu T; Sato Y; Kitagawa K; Kamiya H; Ajioka M; Ishihara M; Dai K; Nanasato M; Sata M; Maemura K; Tomiyama H; Higashi Y; Kaku K; Yamada H; Matsuhisa M; Yamashita K; Bando YK; Kashihara N; Ueda S; Inoue T; Tanaka A; Node K;
    PLoS Med; 2016 Jun; 13(6):e1002051. PubMed ID: 27351380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial.
    Lundby-Christensen L; Tarnow L; Boesgaard TW; Lund SS; Wiinberg N; Perrild H; Krarup T; Snorgaard O; Gade-Rasmussen B; Thorsteinsson B; Røder M; Mathiesen ER; Jensen T; Vestergaard H; Hedetoft C; Breum L; Duun E; Sneppen SB; Pedersen O; Hemmingsen B; Carstensen B; Madsbad S; Gluud C; Wetterslev J; Vaag A; Almdal TP
    BMJ Open; 2016 Feb; 6(2):e008376. PubMed ID: 26916684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.